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OBJECTIVE— To examine the association of glycemic status to magnetic resonance imaging
indicators of brain pathological changes.
RESEARCHDESIGNANDMETHODS— This was a cross-sectional, population-based
study of 4,415 men and women without dementia (mean age 76 years) participating in the Age
Gene/Environment Susceptibility–Reykjavik Study. Glycemic status groups included the follow-
ing: type 2 diabetes (self-report of diabetes, use of diabetes medications, or fasting blood glucose
7.0 mmol/l [11.1%]); impaired fasting glucose (IFG) (fasting blood glucose 5.6–6.9 mmol/l
[36.2%]); and normoglycemic (52.7%). Outcomes were total brain volume, white and gray
matter volume, white matter lesion (WML) volume, and presence of cerebral infarcts.
RESULTS— After adjustment for demographic and cardiovascular risk factors, participants
with type 2 diabetes had significantly lower total brain volume (72.2 vs. 71.5%; P 0.001) and
lower gray and white matter volumes (45.1 vs. 44.9%, P 0.01 and 25.7 vs. 25.3%, P 0.001,
respectively) and were more likely to have single (odds ratio 1.45 [95% CI 1.14–1.85]) or
multiple (2.27 [1.60–3.23]) cerebral infarcts compared with normoglycemic participants.
Longer duration of type 2 diabetes was associated with lower total brain volume and gray and
white matter volume, higher WML volume (all Ptrend 0.05), and a greater likelihood of single
and multiple cerebral infarcts (all Ptrend  0.01).
CONCLUSIONS— Type 2 diabetic participants have more pronounced brain atrophy and
are more likely to have cerebral infarcts. Duration of type 2 diabetes is associated with brain
changes, suggesting that type 2 diabetes has a cumulative effect on the brain.
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The prevalence of type 2 diabetes isincreasing worldwide and the dis-ease has become a significant pub-
lic health problem in individuals of all
ages (1). Previously a disease of middle-
aged and older adults, type 2 diabetes is
rapidly increasing among young peo-
ple, paralleling increasing rates of obe-
sity (2). The number of individuals
worldwide with type 2 diabetes is ex-
pected to increase more than twofold in
the next 30 years, creating a public
health crisis of epidemic proportion (3).
The increasing prevalence and pro-
longed survival of individuals with type
2 diabetes has led to an increase in the
number of individuals developing com-
plications of type 2 diabetes, including
brain changes and associated cognitive
impairment (4 – 6).
Experimental studies have linked
neurodegenerative and vascular damag-
ing mechanisms to characteristics of type
2 diabetes (7–10). Epidemiological stud-
ies have reported evidence for an associa-
tion of type 2 diabetes to brain changes
but have not investigated the association
of type 2 diabetes to brain volume tissue
changes and number and location of ce-
rebral infarcts (5,11). Here, we examined
the association of glycemic status and MRI
findings of brain tissue volumes and cere-
bral infarcts in a population-based cohort
of older men and women who partici-
pated in the Age Gene/Environment
Sus c ep t i b i l i t y–Reyk j av ik S tudy
(AGES-Reykjavik).
RESEARCH DESIGN AND
METHODS— The aim of AGES-
Reykjavik is to investigate the contribu-
tions of environmental factors, genetic
susceptibility, and gene-environment in-
teractions to aging of the neurocognitive,
cardiovascular, musculoskeletal, body
composition, and metabolic systems. De-
tails on the study design and the baseline
AGES-Reykjavik assessments have been
described elsewhere (12). In brief, partic-
ipants are from the cohort of men and
women born in 1907–1935 and living in
Reykjavik who were followed as a part of
the Reykjavik Study initiated in 1967 by
the Icelandic Heart Association (13). In
2002, cohort members were reinvited to
participate in AGES-Reykjavik. Here we
report on 5,764 participants who com-
pleted the AGES-Reykjavik examination,
which included a structured survey in-
strument, cognitive testing, and brain
magnetic resonance imaging (MRI).
AGES-Reykjavik was approved by the
Icelandic National Bioethics Committee
(VSN 00-063), the Icelandic Data Protec-
tion Authority, and the institutional review
board of the U.S. National Institute on Ag-
ing, National Institutes of Health. Informed
consent was provided by all participants.
MRI scanning and reading protocol
Magnetic resonance image acquisition.
High-resolution MRI scans were acquired
on a 1.5-T Signa Twinspeed system (Gen-
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eral Electric Medical Systems, Waukesha,
WI). The image protocol has been de-
scribed previously (12). In brief, it in-
cludes the following pulse sequences: a
proton density/T2-weighted fast spin
echo sequence and a fluid-attenuated in-
version recovery sequence (FLAIR). The
acquisition of these sequences was per-
formed with 3-mm-thick interleaved
slices. In addition, images were acquired
with a T1-weighted three-dimensional
spoiled gradient echo sequence with a
slice thickness of 1.5 mm. All images were
acquired to give full brain coverage, and
slices were angled parallel to the anterior
commissure-posterior commissure line to
give reproducible image views in the ob-
lique-axial plane.
Cerebral infarcts. A cerebral infarct was
defined as a defect of the brain paren-
chyma with a signal intensity that is isoin-
tense to that of cerebrospinal fluid on all
pulse sequences (i.e., FLAIR and proton
density/T2-weighted) and that has a min-
imal diameter of 4 mm, with the excep-
tion of infarcts in the cerebellum, which
had no size criteria. The size (millimeters)
of each infarct was measured at the largest
diameter of the defect irrespective of the
orientation. Image analyses were per-
formed in a two-step procedure. An expe-
rienced neuroradiologist (O.K.) examined
the scan for clinical abnormalities that
needed immediate attention. At the same
time, the neuroradiologist recorded di-
rectly into a shared database the slice lo-
cation of observed cortical and cerebellar
infarcts because identification of these in-
farcts may be more difficult. Trained rat-
ers with access to the shared database
identified subcortical infarcts and then
characterized all of the infarcts in more
radiological detail. Infarcts that spanned
two areas were assigned to the area with
the largest diameter of the infarct.
Postprocessing of MRI scans and brain
tissue volumes. Total brain, white and
gray matter, and white matter lesion
(WML) volumes were computed auto-
matically with an algorithm based on the
Montreal Neurological Institute pipeline
(14). The AGES-Reykjavik/Montreal
Neurological Institute pipeline has been
modified to accommodate full brain cov-
erage including cerebellum and brain-
stem, multispectral images (T1-weighted
three-dimensional spoiled gradient echo
sequence, FLAIR, and proton density/T2-
weighted fast spin echo sequences), high
throughput, and minimal editing. Total
brain volume (an indicator of atrophy)
was derived as the percentage of the total
tissue volume to the intracranial volume.
The other brain tissue classes were simi-
larly adjusted for total intracranial volume
to give a percentage.
Quality control procedures. Every 6
months the intraobserver variability for
each observer and every 3 months the in-
terobserver variability for the whole
group of observers were assessed. The in-
traobserver weighted  statistic was 0.92
for cerebral infarcts; the interobserver
weighted  statistic was 0.66 for cerebral
infarcts.
Glycemic groups
Glycemic groups were defined using
American Diabetes Association cut points
(15). Type 2 diabetes was based on self-
reported doctor’s diagnosis of diabetes,
use of diabetes medications (hypoglyce-
mic medications and insulin), which was
noted from medication vials brought to
the clinic, or a fasting blood glucose level
7.0 mmol/l at the baseline AGES-
Reykjavik examination. The definition of
impaired fasting glucose (IFG) followed
American Diabetes Association criteria of
no type 2 diabetes and a fasting blood
glucose level between 5.6 and 6.9 mmol/l.
In separate analyses we also defined IFG
according to World Health Organization
criteria (fasting glucose levels between 6.1
and 6.9 mmol/l) (16). Measurement of
A1C was performed on a Hitachi 912 in-
strument, with a turbidimetric inhibition
immunoassay for hemolyzed whole blood
from Roche Diagnostics, traceable to the
Diabetes Control and Complications Trial
reference. To further identify factors that
may moderate the association of diabetes
to brain changes, we examined the effects
of duration of disease, as assessed by
questionnaire.
Diagnosis of dementia
Dementia was ascertained by use of a
three-step process that has been de-
scribed elsewhere (12). A consensus diag-
nosis of dementia based on the DSM-IV
guidelines was made by a panel that in-
cluded a geriatrician, neurologist, neuro-
psychologist, and neuroradiologist.
Potential confounders
Based on previous reports (4,11,17), a
number of potentially confounding vari-
ables associated with brain atrophy, cere-
bral infarcts, and diabetes were examined
as potential confounders. Factors that sig-
nificantly differed among glycemic
groups in univariate analyses were in-
cluded as covariates in the final multivar-
iate models. Demographic (age, sex, and
education) and health-related confound-
ing variables were assessed via question-
naire at the AGES-Reykjavik examination.
High depressive symptomatology was
classified as a score of6 on the 15-item
Geriatric Depression Scale (18). We also
controlled for vascular risk factors mea-
sured at the AGES-Reykjavik examina-
tion, including hypertension (self-reported
doctor’s diagnosis of hypertension, use of
hypertensive medications, or systolic
blood pressure 140 mmHg or diastolic
blood pressure 90 mmHg); smoking
status (ever smoker/never smoker) and
physical activity (moderate or more ver-
sus less) assessed via questionnaire; BMI
(calculated from measured height and
weight); and myocardial infarction de-
fined as a self-reported doctor’s diagnosis
or detected on an electrocardiogram.
Analytic sample and strategy
Of the 5,764 participants, 281 were ex-
cluded based on standard MRI contrain-
dications and an additional 834 had
incomplete MRI data (due to claustropho-
bia, equipment failure, refusal, or ability
to participate only in an in-home exami-
nation) or scans could not be processed
successfully, giving a sample of 4,614
MRI scans. Dementia probably confounds
the relationship between brain changes
and type 2 diabetes (11). Therefore, we
excluded subjects with dementia from the
analysis. Of the 4,614 participants with
complete MRI scans, 4,415 did not have
dementia and served as the sample for the
present analysis.
Demographic and health characteris-
tics were compared among the three gly-
cemic groups (normoglycemic, IFG, and
type 2 diabetes) with age-adjusted linear
models for continuous variables and age-
adjusted logistic regression for dichoto-
mous outcomes. Linear regression was
used to examine the association of glyce-
mic groups to brain volume. Multinomial
logistic regression was used to investigate
the association of the glycemic groups
and the presence of a single infarct or
multiple infarcts compared with having
no infarcts. Participants classified as nor-
moglycemic were the reference group in
these analyses. The models were adjusted
for previously described demographic,
health, and cardiovascular factors. In sub-
sequent analyses, we examined the asso-
ciation between duration of type 2
diabetes and brain tissue volumes and the
presence of cerebral infarcts. Among par-
ticipants with type 2 diabetes, we exam-
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ined the association of two markers of
severity of disease, A1C levels and diabe-
tes medication use, to brain tissue vol-
umes and cerebral infarcts.
RESULTS— Of the participants, 53%
were classified as being normoglycemic
(n 2,327), 36% (n 1,599) were clas-
sified as having IFG, and 11% (n  489)
were classified as having type 2 diabetes.
Compared with normoglycemic partici-
pants, those with IGF and type 2 diabetes
were more often men, were more likely to
be smokers, and had higher average BMI
(Table 1). Participants with diabetes had a
higher prevalence of hypertension, were
more likely to have a cerebral infarct, and
were less likely to engage in physical ac-
tivity than normoglycemic participants.
Participants with type 2 diabetes had
more brain atrophy, a lower percentage of
gray matter, and a higher percentage of
WMLs than normoglycemic participants
(Table 1).Those with type 2 diabetes and
with IFG had a lower percentage of white
matter compared with those who were
normoglycemic.
Glycemic groups and brain tissue
volumes and cerebral infarcts
In models adjusted for demographic
characteristics and cardiovascular risk
factors, participants with type 2 diabetes
had significantly lower average total brain
and gray and white matter volumes com-
pared with normoglycemic participants
(Table 2). Participants with type 2 diabe-
tes also had a higher average percentage of
WMLs compared with normoglycemic
participants, but the association was at-
tenuated by adjustment for cardiovas-
c u l a r r i s k f a c t o r s ( m y o c a r d i a l
infarction, smoking, hypertension,
physical activity, and BMI). Participants
with type 2 diabetes were 11⁄2 times
more likely than normoglycemic partic-
ipants to have a single cerebral infarct
and nearly 21⁄2 times more likely to have
multiple infarcts (Table 2).
We also examined the odds of having
cerebral infarcts in specific locations (sub-
cortical, cortical, and cerebellar). We
found that participants with type 2 diabe-
tes were nearly twice as likely to have sub-
cortical and cortical infarcts compared
with participants who were classified as
normoglycemic and that these associa-
tions remained significant after adjust-
ment for demographic and cardiovascular
risk factors, as well as the presence of in-
farcts in other locations (fully adjusted
subcortical odds ratio [OR] 1.74 [95% CI
1.30 –2.33]; fully adjusted cortical OR
1.70 [1.25–2.31]; data not shown). Indi-
viduals with type 2 diabetes were signifi-
cantly more likely than normoglycemic
participants to have cerebellar infarcts
when adjusted for demographic and car-
diovascular risk factors (1.45 [1.12–
1.88]), but the association was slightly
attenuated when adjusted for subcortical
and cortical infarcts and was no longer
significant (1.30 [0.99–1.69]).
IFG was not significantly associated
with the measures of brain tissue volume
or the presence of cerebral infarcts. Re-
sults were similar when World Health Or-
ganization cut points were used for IFG
(data not shown).
Duration of diagnosed diabetes
Of the 489 participants with type 2 dia-
betes, diabetes was diagnosed in 8.5%
(n  41) within the past year, in 19.8%
(n 97) from 1 to 6 years, in 18.2% (n
89) from 7 to 14 years, and in 24.7% (n
121) 15 years before the AGES-
Reykjavik examination; 28.8% (n 141)
had undiagnosed type 2 diabetes that was
identified based on fasting glucose levels
at the in-person examination (i.e., no self-
reported history of type 2 diabetes or
medication use but fasting glucose of
7.0 mmol/l). There was a significant
trend for increasing duration of disease
and lower percentage of total brain vol-
ume (Ptrend 0.001), lower percentage of
gray matter (Ptrend  0.001) and white
matter (Ptrend  0.001), and higher per-
centage of WMLs (Ptrend  0.05) (Table
3). A longer duration of type 2 diabetes
was also associated with significantly
higher odds of having single (Ptrend 
0.004) or multiple (Ptrend  0.001) in-
farcts compared with having no infarcts
(Table 3). Compared with normoglyce-
mic participants, those whose type 2 dia-
betes was diagnosed based on fasting
glucose at the AGES-Reykjavik examina-
tion (undiagnosed type 2 diabetes) also
had lower percentages of total brain vol-
ume and gray matter and were more
likely to have single and multiple in-
farcts (Table 3).
Table 1—Sample description according to glycemic group: AGES-Reykjavik
Normoglycemic IFG
Type 2
diabetes
n 2,327 1,599 489
Age (years) 76.4  5.5 75.9  5.4 76.0  5.4
Education (low) 23.3 22.7 19.0
Sex (female) 65.0 52.5‡ 47.2‡
Depression 7.1 6.0 6.8
MMSE total score 27 (26, 29) 27 (26, 29) 28 (26, 29)
DSST (total correct) 29 (22, 36) 29 (22, 37) 28 (20, 36)
Ever smoker 54.9 58.9* 60.7*
Physical activity (no moderate activity) 43.5 44.0 51.9‡
BMI (kg/m2) 26.1  4.1 27.7  4.3‡ 28.6  4.5‡
Hypertension 75.9 83.0 91.2‡
Myocardial infarction 5.4 5.1 7.4
A1C (%) 5.5 (5.3, 5.7) 5.6 (5.4, 5.8)‡ 6.2 (5.9, 6.8)‡
Fasting glucose 5.2 (5.0, 5.4) 5.9 (5.7, 6.2)‡ 7.4 (6.6, 8.5)‡
Hypoglycemic medication use — 0.1 50.9
Insulin use — — 6.8
Self-reported stroke 6.3 5.2 7.2
Cerebral infarct on MRI 28.0 29.5 43.7‡
Brain volume (% of total intracranial
volume)
Total brain volume 72.25  3.8 72.23  3.9 71.24  3.7‡
Grey matter 45.18  1.8 45.23  1.9 44.66  1.9‡
White matter 25.74  1.3 25.71  1.3* 25.12  1.3‡
WMLs 1.32  3.3 1.29  3.2 1.46  3.2*
Data are means SD, median (25th percentile, 75th percentile), or percent. n 4,415. Glycemic groups are
based on current American Diabetes Association criteria (15). Depression was classified as a score of6 on
the 15-item Geriatric Depression Scale (18). *P 0.05; ‡P 0.001, for age-adjusted comparison with the
normoglycemic group. DSST, Digit Symbol Substitution Test (24); MMSE, Mini-Mental State Examination
(23).
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Disease severity and brain tissue
volumes and cerebral infarcts
As secondary analyses we examined two
measures of disease severity, A1C levels
and diabetes medication use (hypoglyce-
mic medications or insulin), in relation to
brain tissue volumes and presence of ce-
rebral infarcts. Quartiles of A1C were not
associated with brain tissue volumes or
the presence of single or multiple infarcts
(data not shown).
Among participants with type 2 dia-
betes,56% were taking either hypogly-
cemic medications or insulin. Compared
with participants with type 2 diabetes
who did not take diabetes-related medi-
cations, those who took medications had
a significantly lower percentage of total
brain volume (adjusted mean percentage
72.4 vs. 70.9; P  0.001) and lower per-
centage of gray matter (45.4 vs. 44.5; P
0.01) and white matter (25.6 vs. 24.9;
P  0.001) volume. Medication use was
not associated with WML volume or the
presence of cerebral infarcts (data not
shown).
CONCLUSIONS— We examined
the association of type 2 diabetes and IFG
to brain tissue volumes and the presence
of cerebral infarcts in a population-based
cohort of older adults that excluded indi-
viduals with in-study assessed cases of de-
mentia. We found that type 2 diabetes
was associated with lower total brain vol-
ume and with lower gray and white mat-
ter volume. Type 2 diabetic participants
were also more likely to have cerebral in-
farcts, with a greater than twofold in-
crease in the likelihood of having multiple
infarcts over that of normoglycemic par-
ticipants. In addition, the duration of type
2 diabetes was associated with greater at-
rophy and WML volume, lower gray and
white matter volume, and more cerebral
infarcts. We also found that those who
took medications to control diabetes, an
indicator of disease severity, had lower
brain volume than those diabetic partici-
pants not taking medication. These
associations were independent of demo-
graphics and other cardiovascular risk
factors.
Although the percent differences be-
tween normoglycemic participants and
participants with type 2 diabetes are
small, in this cohort, the average annual
decrease in brain tissue volume is
0.43% for total brain volume. Thus, the
average differences in brain tissue vol-
umes in participants with type 2 diabetes
correspond to 2 years of age for loss of
total brain volume.
This study has a number of strengths.
Findings are based on a large, population-
based cohort. Because the cohort is well
characterized with respect to potential
confounding factors, we could adjust our
models with these factors to determine
the direct relation of type 2 diabetes to
brain changes. The use of an automated
brain segmentation method enabled us to
estimate accurate, reproducible, and sen-
sitive volumetric assessments of the brain.
Further, we were able to exclude patients
with clinically diagnosed dementia, thus
reducing the confounding effect of de-
mentia pathology on the association of
type 2 diabetes to brain pathological
changes. However, these findings are
based on cross-sectional data and should
be replicated in longitudinal studies.
Table 2—Association of glycemic groups to diffuse and focal brain changes: AGES–Reykjavik
Normoglycemic* IFG Type 2 diabetes
Tissue volume
Total brain volume
Model 1 72.19 72.27 71.45‡
Model 2 72.25 72.25 71.46‡
Grey matter
Model 1 45.10 45.28 44.86
Model 2 45.12 45.30 44.93†
White matter
Model 1 25.77 25.68 25.11‡
Model 2 25.72 25.73 25.28‡
WMLs
Model 1 1.31 1.31 1.47†
Model 2 1.31 1.29 1.42
Cerebral infarcts
Model 1
Single infarct 1.0 1.00 (0.85–1.17) 1.71 (1.37–2.15)‡
Multiple infarcts 1.0 1.13 (0.87–1.48) 2.65 (1.90–3.69)‡
Model 2
Single infarct 1.0 0.97 (0.82–1.14) 1.45 (1.14–1.85)†
Multiple infarcts 1.0 1.13 (0.86–1.49) 2.27 (1.60–3.23)‡
Data are adjusted mean percentage of total intracranial volume or ORs (95% CI). n  4,415. Model 1 was
adjusted for age, sex, and education. Model 2 included additional adjustments for myocardial infarction,
smoking status, hypertension, BMI, and physical activity. *Reference group is normoglycemic subjects. †P
0.01; ‡P  0.001.
Table 3—Association of duration of diabetes to brain tissues volumes and cerebral infarcts: AGES–Reykjavik
Duration of diabetes
Total brain
volume Grey matter White matter WMLs Single infarct Multiple infarcts
Nondiabetic 72.3 (ref) 45.2 (ref) 25.7 (ref) 1.3 (ref) 1.0 (ref) 1.0 (ref)
1 year 73.0 46.0 25.4 1.6 1.56 (0.79–3.04) 0.82 (0.19–3.54)
1–6 years 71.7 45.0 25.1† 1.5 1.37 (0.84–2.21) 2.70 (1.48–4.91)‡
7–14 years 71.4* 44.9 25.1‡ 1.5 1.95 (1.22–2.21)‡ 2.25 (1.12–4.52)†
15 years 70.9‡ 44.3‡ 25.2‡ 1.3 1.10 (0.70–1.72) 2.02 (1.15–3.58)†
Ptrend 0.001 0.001 0.001 0.048 0.004 0.001
Undiagnosed diabetes 71.3‡ 44.5† 25.4 1.4 1.56 (1.05–2.32)* 2.20 (1.24–3.88)†
Data are adjusted mean percentage (adjusted for age, education, sex, smoking status, myocardial infarction, hypertension, BMI, and physical activity) of total
intracranial volume or ORs (95% CI). n  4,415. Ptrend excludes undiagnosed type 2 diabetes. *P  0.05; †P  0.01; ‡P  0.001. ref, referent.
Saczynski and Associates
DIABETES CARE, VOLUME 32, NUMBER 9, SEPTEMBER 2009 1611
Although evidence from clinical and
epidemiological studies for the vascular
and neurodegenerative effects of type 2
diabetes in the brain is increasing, find-
ings are still mixed, particularly with re-
spect to WML pathology (19,20).
Differences in the measurement of WMLs
in various studies (semiquantitative/
visual scales versus quantitat ive/
volumetric measurements) may, in part,
explain inconsistencies in published
studies. Furthermore, not all studies ad-
justed for confounding; we found that
WML volume was higher in participants
with type 2 diabetes, but this association
was attenuated by other cardiovascular
risk factors.
Findings for an association of type 2
diabetes to global atrophy and the pres-
ence of cerebral infarcts are more consis-
tent than those of type 2 diabetes and
WMLs (5,19,20). Few studies, however,
are based on population-based samples,
and many did not quantitatively estimate
individual tissue class volumes. We found
increased total brain atrophy, reduced
white and gray matter volumes, and a
higher likelihood of having one or more
cerebral infarcts in participants with type
2 diabetes compared with normoglyce-
mic participants. Our findings also sug-
gest that type 2 diabetes may affect both
subcortical and cortical brain tissue and
thus may contribute to impairments in
memory, processing speed, and executive
function (6). Type 2 diabetic participants
were also more likely to have infarcts in
the cerebellum, which may contribute to
impairments in motor function, although
the association was attenuated when ad-
justed for the presence of cortical and
subcortical infarcts.
There are a number of mechanisms
through which type 2 diabetes may affect
the brain. Disruption of the blood-brain
barrier and microvascular changes in type
2 diabetes may contribute to neurodegen-
eration and vascular disease (8). Both ce-
rebrovascular and neurodegenerative
effects of type 2 diabetes have been re-
ported from autopsy series (5,11). Endo-
thelial dysfunction, as a result of oxidative
stress and inflammation, may contribute
to the development of cerebral infarcts
(7,9). Atherosclerosis and hemodynamic
changes in individuals with type 2 diabe-
tes may lead to microvascular changes
that are associated with cerebral infarcts
and subcortical atrophy (10,17).
Disease-specific factors may also con-
tribute to brain changes in type 2 diabe-
tes. We found that duration of type 2
diabetes was associated with total brain
atrophy as well as with smaller gray and
white matter volumes and larger WML
volumes, suggesting that prolonged hy-
perglycemic and other metabolic changes
that occur in diabetes may contribute to
pervasive diffuse brain atrophy as well as
focal lesions. In particular, we found that
disease duration of 1 year was associ-
ated with the greatest differences in brain
tissue volume. However, participants
with diabetes diagnosed in the past year
had tissue volumes similar to nondiabetic
subjects.
Our findings on disease control and
brain changes were mixed. We found that
diabetes medication use, potentially a
marker for severity of disease, was associ-
ated with lower total brain volume and
lower gray and white matter volume but
not with WML volume or cerebral in-
farcts. Further, A1C levels were not asso-
ciated with any of the MRI outcomes.
More work is needed to understand the
association between control of type 2 di-
abetes and the brain, a question currently
being investigated in the Action to Con-
trol Cardiovascular Risk in Diabetes
Memory in Diabetes Study (ACCORD-
MIND) trial (21).
These findings based on our popula-
tion-based cohort of subjects without de-
mentia, in conjunction with many studies
based on smaller or clinical samples, ar-
gue for the adoption of diffuse cerebral
disease as another complication of diabe-
tes. These lesions may be the structural
basis for the cognitive impairment in in-
dividuals with diabetes (6). Finally, the
lack of association between pre-diabetic
states (e.g., IFG and impaired glucose tol-
erance) and measures of brain atrophy
and the presence of cerebral infarcts ob-
served in our study and other studies (5)
is in contrast with a dose-response hy-
pothesis of hyperglycemia and brain
changes in type 2 diabetes. However, our
findings on duration of diabetes suggest
that prolonged exposure to hyperglyce-
mia is necessary to observe brain changes
associated with type 2 diabetes. Duration
of type 2 diabetes, pre-diabetic states such
as IFG, and specific mechanisms for the
association between hyperglycemia and
brain changes warrant further investigation.
Our data suggest that type 2 diabetes
has a cumulative effect on the brain. With
the declining age at which individuals are
developing type 2 diabetes and the in-
creasing survival in patients with type 2
diabetes, more patients will be at risk for
developing complications of type 2 diabe-
tes including brain changes. The large in-
crease in the type 2 diabetic population
that is projected to occur over the next 30
years constitutes a significant public
health problem. Brain changes and corre-
sponding cognitive dysfunction (5,6) in
type 2 diabetic subjects have implications
for diabetes management and self-care,
particularly as the complexity of disease
management increases in the older pa-
tient (22).
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